Dendritic cell therapy augments antitumor immunity triggered by CDK4/6 inhibition and immune checkpoint blockade by unleashing systemic CD4 T-cell responses
Abstract
Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy are a mainstay treatment for hormone receptor-positive breast cancer. While their principal mechanism is inhibition of cancer cell proliferation, preclinical and clinical evidence suggests that CDK4/6i can also promote antitumor T-cell responses. However, this pro-immunogenic property is yet to be successfully harnessed in the clinic, as combining CDK4/6i with immune checkpoint blockade (ICB) has not shown a definitive benefit in patients.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- May 01, 2023
- Source ID
- 10.1136/jitc-2022-006019
Entities
People
- Amrendra Kumar
- Ann Richmond
- Anna E Vilgelm
- Carlos L Arteaga
- Chengli Shen
- Daniel De Lima Bellan
- Nabil Saleh
- Roman Uzhachenko
- Sangeetha M Reddy
- Vijay Ramani
- Vijaya Bharti
Organizations
- Cancer Prevention and Research Institute of Texas
- National Institutes of Health
- The Breast Cancer Research Foundation
- United States Department of Defense
- United States Department of Veterans Affairs
- University of Texas Southwestern Medical Center